COPD: antiplatelet therapy and all-cause mortality | COPD

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Antiplatelet therapy in chronic obstructive pulmonary disease (COPD) may significantly lower all-cause mortality.

 

Study design/methods

  • Literature search identified 5 studies including 11117 COPD patients (3069 with acute exacerbation; 33% with ischemic heart disease [IHD]) for systematic review and meta-analysis.

 

Key Results

  • Antiplatelet therapy was common (47%; 95%CI 46%-48%; range 26%-61%).
  • All-cause mortality was significantly lower in COPD patients receiving antiplatelet treatment (odds ratio [OR] 0.81; 0.75-0.88), both in outpatients and in those with acute exacerbation.
  • Antiplatelet therapy was effective independent of potential confounders including IHD, cardiovascular drugs and cardiovascular risk factors, based on meta-regression.

 

Limitations

  • Limitations include those inherent in the included studies.

 

Why this matters

  • Patients with chronic obstructive pulmonary disease (COPD) are at high cardiovascular risk due to chronic inflammation and heightened platelet activation; meta-analysis suggests significantly lower all-cause mortality with antiplatelet therapy.